clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Yamamoto S et al. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. 2017 Biochem. Biophys. Res. Commun. pmid:27998764
Santos MA et al. Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. 2017 Am. J. Med. pmid:27984010
Hiroi S et al. Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. 2017 BMJ Open pmid:28760790
Jenkins H et al. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. 2017 Clin Drug Investig pmid:27928738
Takemoto Y et al. Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. 2017 Intern. Med. pmid:28717096
Alba C et al. Antibiotic resistance in Helicobacter pylori. 2017 Curr. Opin. Infect. Dis. pmid:28704226
Mishima E et al. Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. 2017 Intern. Med. pmid:28674358
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Shimoyama T et al. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. 2017 Intern. Med. pmid:28674348
Ustundag GH et al. The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. 2017 Can J Gastroenterol Hepatol pmid:28656129
Peng X et al. Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. 2017 Int J Med Sci pmid:28638276
Stieler Stewart AL et al. Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. 2017 Equine Vet. J. pmid:28238211
Tsugawa K et al. Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. 2017 Clin. Exp. Nephrol. pmid:27614743
Bewick J et al. The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. 2017 Clin Otolaryngol pmid:27223120
Legendre T et al. [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. 2017 Encephale pmid:27178256
Choi HS et al. Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. 2017 Jpn. J. Infect. Dis. pmid:27169951
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Pastukh N et al. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. 2017 Helicobacter pmid:29058343
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Van der Paardt AL et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. 2017 Eur. Respir. J. pmid:28331034
Souto Filho JTD et al. Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. 2017 Ann. Hematol. pmid:28315923
Antonakos N et al. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. 2017 Crit Care pmid:28274246
Koratala A et al. Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. 2017 Blood Purif. pmid:28268216
McCallum GB et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. 2017 Cochrane Database Syst Rev pmid:28828759
de Ávila BE et al. Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. 2017 Nat Commun pmid:28814725
Zhang D et al. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. 2017 Medicine (Baltimore) pmid:28796053
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Jung YS et al. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28776746
Makihara K et al. Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. 2017 Cancer Chemother. Pharmacol. pmid:28711984
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Iwayama K et al. Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. 2017 BMC Pharmacol Toxicol pmid:28235416
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Awan S et al. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. 2017 Lung Cancer pmid:28213005
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Huang CC et al. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. 2018 J Microbiol Immunol Infect pmid:28705770
Kelly C et al. Macrolide antibiotics for bronchiectasis. 2018 Cochrane Database Syst Rev pmid:29543980
Mégraud F Antibiotic Resistance Is the Key Element in Treatment of Helicobacter pylori Infection. 2018 Gastroenterology pmid:30308190
Mieras LF et al. An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. 2018 BMC Infect. Dis. pmid:30290790
Liou JM et al. Toward population specific and personalized treatment of Helicobacter pylori infection. 2018 J. Biomed. Sci. pmid:30285834
Liu HY et al. Bilateral Non-tuberculous Mycobacterial Keratitis After Small Incision Lenticule Extraction. 2018 J Refract Surg pmid:30199569
Kabakambira JD et al. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial. 2018 BMC Gastroenterol pmid:30165823
Yotsu RR et al. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). 2018 Cochrane Database Syst Rev pmid:30136733
Tang D et al. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment]. 2018 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:30124214
Byeon JY et al. Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. 2018 Arch. Pharm. Res. pmid:30117082
Park CG et al. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: A prospective, observational study. 2018 Medicine (Baltimore) pmid:30113472
Morgene MF et al. HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. 2018 Virology pmid:30077071
Shinozaki S et al. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen. 2018 Kaohsiung J. Med. Sci. pmid:30041763
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Heffernan CB et al. Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. 2018 Ann. Otol. Rhinol. Laryngol. pmid:30032669
Hamza D et al. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. 2018 Microb. Pathog. pmid:30031039
Vianna JS et al. The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori. 2018 Rev. Inst. Med. Trop. Sao Paulo pmid:29972462
Abu-Khalaf N et al. The Taste of Commercially Available Clarithromycin Oral Pharmaceutical Suspensions in the Palestinian Market: Electronic Tongue and In Vivo Evaluation. 2018 Sensors (Basel) pmid:29401675
Chai KY et al. Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report. 2018 J Med Case Rep pmid:29743095
Strouvalis I et al. Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence. 2018 Respirology pmid:29741298
Long X et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. 2018 Helicobacter pmid:29696736
Fiorini G et al. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. 2018 Scand. J. Gastroenterol. pmid:29688095
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Rodríguez-Sevilla G et al. Influence of three-dimensional lung epithelial cells and interspecies interactions on antibiotic efficacy against Mycobacterium abscessus and Pseudomonas aeruginosa. 2018 Pathog Dis pmid:29648588
Namkoong H et al. Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. 2018 PLoS Pathog. pmid:29621339
Berende A et al. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. 2018 PLoS ONE pmid:29608590
Mabe K et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. 2018 J. Infect. Chemother. pmid:29605555
Chen SA et al. HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients. 2018 Basic Clin. Pharmacol. Toxicol. pmid:29575644
van Dyk M et al. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. 2018 Eur. J. Clin. Pharmacol. pmid:29572563
Chen J et al. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29562911
Rodríguez-Sevilla G et al. Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model. 2018 Int. J. Med. Microbiol. pmid:29555180
Leung WK et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. 2018 Gastroenterology pmid:29550592
Kusuki M et al. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis. 2018 Diagn. Microbiol. Infect. Dis. pmid:29550059
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Reisfeld L et al. Cutaneous mycobacteriosis in a captive Amazonian manatee Trichechus inunguis. 2018 Dis. Aquat. Org. pmid:29516862
Wang YH et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. 2018 Helicobacter pmid:29405526
Tso S et al. Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid. 2018 BMJ Case Rep pmid:29374651
Sahara S et al. Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. 2018 Digestion pmid:29310119
Aderemi AO et al. Oxidative stress responses and cellular energy allocation changes in microalgae following exposure to widely used human antibiotics. 2018 Aquat. Toxicol. pmid:30125766
Sue S et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. 2018 Helicobacter pmid:29271026
Nakase K et al. Long-term administration of oral macrolides for acne treatment increases macrolide-resistant Propionibacterium acnes. 2018 J. Dermatol. pmid:29235673
Cho EH et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. 2018 J. Infect. Chemother. pmid:29223615
Compain F et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. 2018 Diagn. Microbiol. Infect. Dis. pmid:29217419
Li H et al. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. 2018 Scand. J. Gastroenterol. pmid:29214879
Jung JH et al. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Infection. 2018 Gut Liver pmid:29212313
Deng J et al. Lack of additional effects of long-term, low-dose clarithromycin combined treatment compared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial. 2018 Int Forum Allergy Rhinol pmid:29195025
Beer-Davidson G et al. Detection of Helicobacter pylori in stool samples of young children using real-time polymerase chain reaction. 2018 Helicobacter pmid:29181860
Muñoz-Gómez P et al. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. 2018 Helicobacter pmid:29178562
Zagari RM et al. Treatment of Helicobacter pylori infection: A clinical practice update. 2018 Eur. J. Clin. Invest. pmid:29144559
Liu DS et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. 2018 Clin. Microbiol. Infect. pmid:29138101
Marsousi N et al. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. 2018 Biopharm Drug Dispos pmid:28960401
De Lorenzi G et al. Mycobacterium genavense Infection in a Domestic Ferret (Mustela putorius furo). 2018 Top Companion Anim Med pmid:30502861
McNicholl AG et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. 2018 Helicobacter pmid:30141228
Silva GM et al. Helicobacter pylori antimicrobial resistance in a pediatric population. 2018 Helicobacter pmid:30091503
Popovic V et al. Mycobacterium shimoidei-cavitary pulmonary disease with favorable outcome. 2018 Folia Microbiol. (Praha) pmid:28913757
Mahachai V et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. 2018 J. Gastroenterol. Hepatol. pmid:28762251
Bilgilier C et al. Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. 2018 Clin. Microbiol. Infect. pmid:28669844
Barros S et al. Cat Scratch Disease: Not a Benign Condition. 2018 Ocul. Immunol. Inflamm. pmid:28665750
Hosono Y et al. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. 2018 J. Infect. Chemother. pmid:29361415
Yoshida S et al. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan. 2018 J. Med. Microbiol. pmid:29227218
Alenezi A et al. Controlled release of clarithromycin from PLGA microspheres enhances bone regeneration in rabbit calvaria defects. 2018 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:28067984
Choi IJ et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. 2018 N. Engl. J. Med. pmid:29562147
Ribaldone DG et al. Helicobacter pylori eradication: poor medical compliance from East to West of the world. 2018 Scand. J. Gastroenterol. pmid:29383955
Suzuki K et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. 2018 Respir Investig pmid:29325687